Novo Nordisk ramps up legal case against compounding pharmacies selling ‘misbranded’ semaglutide

No­vo Nordisk is tak­ing an­oth­er Flori­da phar­ma­cy to court af­ter al­leged­ly find­ing im­pu­ri­ties in its com­pound­ed drugs mar­ket­ed as semaglu­tide, in­clud­ing one sam­ple that was 33% im­pure, ac­cord­ing to court doc­u­ments.

It’s the lat­est in a string of law­suits filed by No­vo and its ri­val Eli Lil­ly in an at­tempt to stop well­ness cen­ters and com­pound­ing phar­ma­cies from what they be­lieve is im­prop­er mar­ket­ing of the pop­u­lar di­a­betes and weight loss prod­ucts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.